Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P00451
UPID:
FA8_HUMAN
Alternative names:
Antihemophilic factor; Procoagulant component
Alternative UPACC:
P00451; Q14286; Q5HY69
Background:
Coagulation factor VIII, also known as Antihemophilic factor, plays a pivotal role in blood coagulation by acting as a cofactor for factor IXa in the conversion of factor X to its activated form, factor Xa. This process is essential for the formation of a stable blood clot.
Therapeutic significance:
The dysfunction of factor VIII is directly linked to Hemophilia A, a disorder characterized by a tendency to hemorrhage, and Thrombophilia 13, X-linked, due to factor VIII defect, associated with severe thrombophilia. Understanding the role of Coagulation factor VIII could open doors to potential therapeutic strategies for these bleeding disorders.